Navigation überspringen
Universitätsbibliothek Heidelberg
Status: Bibliographieeintrag

Verfügbarkeit
Standort: ---
Exemplare: ---
heiBIB
 Online-Ressource
Verfasst von:Frühauf, Stefan [VerfasserIn]   i
 Ehninger, G. [VerfasserIn]   i
 Hübel, K. [VerfasserIn]   i
 Topaly, Julian [VerfasserIn]   i
 Goldschmidt, Hartmut [VerfasserIn]   i
 Ho, Anthony Dick [VerfasserIn]   i
 Müller, S. [VerfasserIn]   i
 Moos, Marion [VerfasserIn]   i
 Badel, K. [VerfasserIn]   i
 Calandra, G. [VerfasserIn]   i
Titel:Mobilization of peripheral blood stem cells for autologous transplant in non-Hodgkin's lymphoma and multiple myeloma patients by plerixafor and G-CSF and detection of tumor cell mobilization by PCR in multiple myeloma patients
Verf.angabe:S. Fruehauf, G. Ehninger, K. Hübel, J. Topaly, H. Goldschmidt, A. D. Ho, S. Müller, M. Moos, K. Badel and G. Calandra
Jahr:2010
Jahr des Originals:2009
Umfang:7 S.
Fussnoten:Published online 13 July 2009 ; Gesehen am 12.01.2022
Titel Quelle:Enthalten in: Bone marrow transplantation
Ort Quelle:London : Springer Nature, 1997
Jahr Quelle:2010
Band/Heft Quelle:45(2010), 2, Seite 269-275
ISSN Quelle:1476-5365
Abstract:This report describes the first investigational use of plerixafor in Europe and the determination of tumor cell mobilization by polymerase chain-reaction after plerixafor treatment in a subset of patients with multiple myeloma (MM). Thirty-five patients (31 MM and 4 NHL) received granulocyte colony-stimulating factor (G-CSF) (10 μg/kg) each morning for 4 days. Starting the evening of Day 4, patients recieved plerixafor 0.24 mg/kg. Apheresis was initiated 10-11 h later, in the morning of Day 5. This regimen of G-CSF treatment each morning before apheresis and plerixafor treatment in the evening was repeated for up to 5 consecutive days. Mobilization with plerixafor and G-CSF resulted in a median 2.6-fold increase in peripheral blood (PB) CD34+ cell count compared with before plerixafor treatment. All patients collected ⩾2 × 106 CD34+ cells/kg and 32 of 35 patients collected ⩾5 × 106 CD34+ cells/kg. After plerixafor treatment, 3 of 7 patients had a small increase and 4 of 7 patients had a small decrease in PB tumor cells. No G-CSF was given post transplant. The median number of days to polymorphonuclear leukocyte and platelet engraftment was 14.0 and 11.0, respectively. There were no reports of graft failure. Plerixafor was generally well tolerated. Mobilization of PB CD34+ cells was consistent with previous clinical trials. The addition of plerixafor did not significantly increase the relative number of PB MM tumor cells.
DOI:doi:10.1038/bmt.2009.142
URL:Bitte beachten Sie: Dies ist ein Bibliographieeintrag. Ein Volltextzugriff für Mitglieder der Universität besteht hier nur, falls für die entsprechende Zeitschrift/den entsprechenden Sammelband ein Abonnement besteht oder es sich um einen OpenAccess-Titel handelt.

Volltext ; Verlag: https://doi.org/10.1038/bmt.2009.142
 Volltext: https://www.nature.com/articles/bmt2009142
 DOI: https://doi.org/10.1038/bmt.2009.142
Datenträger:Online-Ressource
Sprache:eng
Sach-SW:Cell Biology
 general
 Hematology
 Internal Medicine
 Medicine/Public Health
 Public Health
 Stem Cells
K10plus-PPN:1785855441
Verknüpfungen:→ Zeitschrift

Permanenter Link auf diesen Titel (bookmarkfähig):  https://katalog.ub.uni-heidelberg.de/titel/68865705   QR-Code
zum Seitenanfang